Seattle Genetics (SGEN) Tops Q4 EPS by 3c

Seattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.22), $0.03 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $74.3 million versus the consensus estimate of $68.34 million.

Seattle Genetics anticipates 2015 revenues from ADCETRIS net product sales to be in the range of $200 million to $210 million and 2015 revenues from collaboration and license agreements to be in the range of $60 million to $70 million. Collaboration revenues will be generated from fees, milestones and reimbursements earned through the company’s ADCETRIS and ADC collaborations.

For earnings history and earnings-related data on Seattle Genetics (SGEN) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Reaction roundup: Experts, analysts weigh in on September jobs report
• Freeport Q3 2026 copper output meets targets; gold sales deferred